NS 11

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584828

CAS#: 150044-75-0

Description: NS 11 is an RGD-nonpeptidic mimetic.

Chemical Structure

img
NS 11
CAS# 150044-75-0
Instruction

Theoretical Analysis

MedKoo Cat#: 584828
Name: NS 11
CAS#: 150044-75-0
Chemical Formula: C14H25N5O4
Exact Mass: 327.19
Molecular Weight: 327.385
Elemental Analysis: C, 51.36; H, 7.70; N, 21.39; O, 19.55

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: NS 11; NS11; NS-11

IUPAC/Chemical Name: beta-Alanine, N-((1-(4-((aminoiminomethyl)amino)-1-oxobutyl)-3-piperidinyl)carbonyl)-

InChi Key: SNOGWDOUFKAQIY-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H25N5O4/c15-14(16)18-6-1-4-11(20)19-8-2-3-10(9-19)13(23)17-7-5-12(21)22/h10H,1-9H2,(H,17,23)(H,21,22)(H4,15,16,18)

SMILES Code: O=C(O)CCNC(C1CN(C(CCCNC(N)=N)=O)CCC1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 327.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin Daniel W. Bougie, Mark Rasmussen, Jieqing Zhu, Richard H. Aster Blood. 2012 Jun 28; 119(26): 6317–6325. Prepublished online 2012 Apr 6. doi: 10.1182/blood-2012-01-406322 PMCID: PMC3383197

2: Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban Shaker A Mousa, Jeffrey M Bozarth, Ulhas P Naik, Andrew Slee Br J Pharmacol. 2001 Jun; 133(3): 331–336. doi: 10.1038/sj.bjp.0703943 PMCID: PMC1572788

3: Lymphocyte Adhesion to Candida albicans Christopher B. Forsyth, Herbert L. Mathews Infect Immun. 2002 Feb; 70(2): 517–527. doi: 10.1128/IAI.70.2.517-527.2002 PMCID: PMC127679

4: Pharmacological inhibition of β3 integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity Ashley Browne, Laura A. Tookman, Carin K. Ingemarsdotter, Russell D. Bouwman, Katrina Pirlo, Yaohe Wang, Iain A. McNeish, Michelle Lockley Cancer Res. Author manuscript; available in PMC 2016 Jan 15.Published in final edited form as: Cancer Res. 2015 Jul 15; 75(14): 2811–2821. Published online 2015 May 14. doi: 10.1158/0008-5472.CAN-14-3761 PMCID: PMC4506788

5: Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer Andrew R. Reynolds Dose Response. 2010; 8(3): 253–284. Published online 2010 Apr 23. doi: 10.2203/dose-response.09-049.Reynolds PMCID: PMC2939687

6: The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury. R. Bruck, R. Hershkoviz, O. Lider, H. Shirin, H. Aeed, Z. Halpern Yale J Biol Med. 1997 Jul-Aug; 70(4): 391–402.PMCID: PMC2589337

7: αvβ3 Integrin Limits the Contribution of Neuropilin-1 to Vascular Endothelial Growth Factor-induced Angiogenesis Stephen D. Robinson, Louise E. Reynolds, Vassiliki Kostourou, Andrew R. Reynolds, Rita Graça da Silva, Bernardo Tavora, Marianne Baker, John F. Marshall, Kairbaan M. Hodivala-Dilke J Biol Chem. 2009 Dec 4; 284(49): 33966–33981. Published online 2009 Oct 16. doi: 10.1074/jbc.M109.030700 PMCID: PMC2797167

8: A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. V. W. Engleman, G. A. Nickols, F. P. Ross, M. A. Horton, D. W. Griggs, S. L. Settle, P. G. Ruminski, S. L. Teitelbaum J Clin Invest. 1997 May 1; 99(9): 2284–2292. doi: 10.1172/JCI119404 PMCID: PMC508061

9: Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators Alessandra Tolomelli, Paola Galletti, Monica Baiula, Daria Giacomini Cancers (Basel) 2017 Jul; 9(7): 78. Published online 2017 Jul 5. doi: 10.3390/cancers9070078 PMCID: PMC5532614

10: Anti-thrombotic agents derived from snake venom proteins Tur-Fu Huang, Chun-Chieh Hsu, Yu-Ju Kuo Thromb J. 2016; 14(Suppl 1): 18. Published online 2016 Oct 4. doi: 10.1186/s12959-016-0113-1 PMCID: PMC5056499

11: Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective αvβ1 Integrin Inhibitors Nilgun Isik Reed, You-Zhi Tang, Joel McIntosh, Yibing Wu, Kathleen S. Molnar, Annafelicia Civitavecchia, Dean Sheppard, William F. DeGrado, Hyunil Jo ACS Med Chem Lett. 2016 Oct 13; 7(10): 902–907. Published online 2016 Aug 30. doi: 10.1021/acsmedchemlett.6b00196 PMCID: PMC5066160